Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:46 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis
NCT05180422 · Criterium, Inc. · PHASE1/PHASE2 · withdrawn · last registry update 2023-10-18 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of enrollment” | Open Targets' class: insufficient enrollment | Registry record, Criterium, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against KRAS in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-07-11Phase 3 first posted: Hoffmann-La Roche, Divarasib + Sotorasib (NCT06497556)
- 2024-03-29Also stopped (withdrawn): NYU Langone Health, Sotorasib + Ladarixin (NCT05815186)
- 2024-01-23Also stopped (withdrawn): M.D. Anderson Cancer Center, Durvalumab + Adagrasib (NCT05848843)
- 2023-07-17Also stopped (withdrawn): Fox Chase Cancer Center, Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days) (NCT05400577)
- 2023-06-27Phase 3 first posted: Amgen, Sotorasib + Pembrolizumab (NCT05920356)
- 2023-05-10Results posted on the registry: Amgen, AMG 510 + Docetaxel (NCT04303780)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision